Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
Objective: To analyze the response to dose-dense chemotherapy of weekly paclitaxel and 3-weekly carboplatin in recurrent ovarian cancer, and to report results of literature review. Materials and methods: Patients accepted weekly paclitaxel 80 mg/m2 on day 1, 8, 15 and carboplatin on day1 at area und...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2020-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_3e6037a9d22d4bbd83ed42e48c9f5e65 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Wei-Chun Chen |e author |
| 700 | 1 | 0 | |a Huei-Jean Huang |e author |
| 700 | 1 | 0 | |a Ting-Chang Chang |e author |
| 700 | 1 | 0 | |a Hung-Hsueh Chou |e author |
| 245 | 0 | 0 | |a Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer |
| 260 | |b Elsevier, |c 2020-01-01T00:00:00Z. | ||
| 500 | |a 1028-4559 | ||
| 500 | |a 10.1016/j.tjog.2019.10.003 | ||
| 520 | |a Objective: To analyze the response to dose-dense chemotherapy of weekly paclitaxel and 3-weekly carboplatin in recurrent ovarian cancer, and to report results of literature review. Materials and methods: Patients accepted weekly paclitaxel 80 mg/m2 on day 1, 8, 15 and carboplatin on day1 at area under curve (AUC) 6 every 21 days were reviewed for the response rate, progression-free survival, overall survival, and toxicity during January 2012 to April 2016 in Chang Gung Memorial Hospital at Linkou, Taiwan. Results: Sixteen patients with recurrent ovarian cancer, including 1 platinum-resistant, 7 partially platinum-sensitive, and 8 platinum-sensitive, accepted a median of 6 cycles of chemotherapy (range 3-10). The overall response rate (ORR) and complete response (CR) rate were 93.8%, and 62.5%, respectively. The median PFS of all patients were 10.9 months (range 4.3-40.5). The median time to response (TTR) was 29.0 days (range 19.6-38.4). The median disease-free survival (DFS) after CR was 5.6 months (range 1.2-34.2). Grade 3 at least toxicity included anemia (6.3%), neutropenia (50%), and thrombocytopenia (18.8%).Twenty-nine articles on phase I, II, III, or retrospective studies of dose-dense chemotherapy with weekly paclitaxel were reviewed. Conclusion: This is the first report using Japanese Gynecologic Oncology Group 3016 protocol, weekly paclitaxel and 3-weely carboplatin, on recurrent ovarian cancer. The current study showed high ORR and CR with tolerable toxicities. Our study suggested dose-dense chemotherapy with paclitaxel, especially combining carboplatin created high efficacy probably by anti-angiogenesis. However, consolidation or maintenance therapy is needed to prolong DFS. Keywords: Dose-dense chemotherapy, Metronomic chemotherapy, Weekly paclitaxel, Carboplatin, Recurrent ovarian cancer | ||
| 546 | |a EN | ||
| 690 | |a Gynecology and obstetrics | ||
| 690 | |a RG1-991 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Taiwanese Journal of Obstetrics & Gynecology, Vol 59, Iss 1, Pp 21-27 (2020) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1028455919302451 | |
| 787 | 0 | |n https://doaj.org/toc/1028-4559 | |
| 856 | 4 | 1 | |u https://doaj.org/article/3e6037a9d22d4bbd83ed42e48c9f5e65 |z Connect to this object online. |